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Drug action(s), drug marketing, and clinical  
medicine. Suppression of ventricular  
arrhythmogenicity with If blockade in human heart 
failure: emerging clinical evidence for ivabradine 
treatment benefit beyond heart rate control
Mechanizm(y) działania leku, strategia marketingowa producenta a medycyna  
kliniczna. Redukcja „automatycznej” arytmogenności komorowej przez hamowanie 
kanałów If w mięśniu lewej komory u pacjentów z niewydolnością serca: podstawy 
patofizjologiczne i pojawiające się dowody kliniczne na korzystne działanie  
iwabradyny poza kontrolą rytmu serca
Piotr Musiałek
Department of Cardiac and Vascular Diseases, Jagiellonian University Institute of Cardiology, John Paul II Hospital, Krakow, Poland
INTRODUCTION
Ivabradine has been continually marketed as “a pure heart rate 
lowering agent” (ditto) [1] whose “cardiac effects are specific 
to the sinus node” (ditto) [1]. A recent article in “Kardiologia 
Polska” [2] contributes importantly to the accumulating evi-
dence that the cardiac effects of ivabradine are not only wider 
than specified by the manufacturer’s (simplified) marketing 
strategies but are also relevant to clinical cardiology [2]. This is 
not surprising because it is in agreement with a sizeable body 
of consistent animal data generated over the years and with 
reproducible studies in human myocardial tissue. 
The role of marketing is to provide simple solutions 
to questions made look simple. Drug marketing, in the pro- 
cess of simplifying the acquisition and evaluation of new 
product information [3, 4], has a fundamental task to make 
the clinical answers and pharmacological solutions look sim-
ple. Today, drug marketing exerts a significant effect on the 
knowledge and awareness of physicians [3, 4]. Despite a num-
ber of clear downsides [3, 4], drug marketing is perceived as 
being associated with several advantages that, according to 
physicians, include easy exposure to new information, time 
saved on searching and accessing journal articles, easiness 
to remember the new information, and facilitated access 
to information on alternative pharmacological agents and 
strategies [3, 4]. 
The role of the physician is to treat diseases that are often 
complex. Reality, and biological reality in particular, proves of-
ten more complex than the marketing strategies would desire. 
Ivabradine exhibits its pharmacological action by inhibit-
ing the If current [5], which, due to its function in the heart, is 
often labelled the ‘pacemaker’ current [5]. In normal hearts, 
f-channels (HCN channels) are functionally expressed exclu-
sively in the sinoatrial node cell membrane [5]. If is a mixed 
sodium and potassium current that is spontaneously activated 
at negative cell membrane potentials [5]. The flow of If causes 
spontaneous diastolic depolarisations and evokes spontaneous 
action potentials [5]. In the healthy heart, the treatment effect 
of ivabradine is indeed limited to the sinoatrial node because 
in the healthy heart the functional expression of f-channels is 
limited to the sinoatrial node cells [5]. 
There is robust evidence that myocardial disease alters 
the electrophysiological properties of the cardiac cells [6, 7]. 
In heart failure (HF) in man, one of the important disease-in-
duced alterations is functional expression of the f-channels 
in the ”ventricular” myocardium [6, 7]. This pathologic ex-
pression of If in human ventricular myocytes provides a basis 
[6, 7] for If-dependent spontaneous action potentials that 
may propagate in the ventricular myocardium [6, 8, 9]. Elec-
trocardiography (ECG) manifestation of the If-driven ectopic 
electrical activity may involve (depending on local tissue con-
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ditions and external stimuli such as adrenergic activation [6]) 
isolated ventricular extrasystoles or runs of ventricular extra-
systoles [10, 11]. 
In the era of powerful marketing-made-easy, clinicians 
(in contrast to investigators performing basic research in 
cardiology using human tissue [6, 7, 12] or animal models 
with gene transfer to mimic human disease [8, 9]) have re-
mained largely unaware of the “ventricular” role of If in HF. 
Why is this “other” role of the If current in the human heart 
not generally known? The reasons seem to be several-fold 
and stems from the following: (1) pivotal clinical trials of 
ivabradine excluded subjects with high arrhythmogenic po-
tential (history of ventricular tachycardia [VT] or implantable 
cardioverter-defibrillator [ICD], recent shock(s) as fundamental 
exclusion criteria [13]); (2) neglect (in contrast to more recent 
trials in HF [14]) of arrhythmic death and/or aborted arrhyth-
mic death as a registered study endpoint [13, 15]; (3) poor 
sensitivity to findings from large studies suggesting reduction 
of ventricular arrhythmogenicity with ivabradine [16]; and 
(4) lack, until today [2], of clinical studies designed to address 
the anti-arrhythmic effect of If inhibition in ventricular myo-
cytes in human HF [6, 7, 10]. 
The above, taken together with the marketing drive for 
“simple” messages [3, 4], may explain why the anti-arrhythmic 
effect of If blockade in ventricular myocardium with ivabra-
dine treatment in human HF has not made it to wide aware-
ness of the clinical community.
IF-DEPENDENT VENTRICULAR  
ARRHYTHMOGENECITY: MECHANISMS  
AND EXPERIMENTAL EVIDENCE
Several lines of evidence indicate that in failing ventricular 
myocytes functional expression of the If current can (similar 
to the If physiologic action in the sinoartial node) contribute 
to spontaneous diastolic depolarisations, spontaneous action 
potentials, and ventricular arrhythmogenicity. What in the 
sinoatrial node is manifested as a normal If-dependent sponta-
neous pacemaker activity, in diseased ventricular myocardium 
shows as ectopic electrical activity and ventricular arrhythmia 
in the form of isolated extrasystoles or runs of extrasystoles 
that, if fast enough, may constitute non-sustained VT or VT 
[10, 17]. Although there appear to be some differences in 
the If molecular basis and regulation in the sinoatrial node 
vs. ventricular myocardium [5–7, 10, 11, 18, 19], there is no 
doubt that in both locations If is highly responsive to adren-
ergic stimulation and is inhibited with ivabradine [5–7, 10]. 
In myopathic ventricular cells in human HF catecholamines 
shift the If activation threshold towards less negative potentials 
and thus the current becomes functional at typical diastolic 
potentials [6]. Beta-adrenergic stimulation also elevates the 
amplitude of If in pathologic ventricular myocytes [6], in-
creasing the role of If-dependent ectopic electrical activity as 
an arrhythmogenic mechanism [6, 7, 10]. This is consistent 
with the well-known pro-arrhythmogenic effect of endo- or 
exogenous adrenergic stimulation in HF [11, 20] and the role 
of catecholamines as an established trigger of ventricular ar-
rhythmia and sudden death in HF [20, 21]. 
If blockers (including ivabradine — the only If blocker in 
clinical use today) inhibit ventricular f-channels through the 
same mode of action as in the sinoatrial node cells [5, 6, 22]. 
Ventricular If contribution to the increased risk of ma-
lignant ventricular arrhythmias and sudden death through 
favouring spontaneous diastolic depolarisation in ventricular 
myocytes [22, 23], has been recently studied in a model of 
forced expression of f-channels in normal myocardium using 
somatic gene transfer [8]. These studies demonstrated that 
f-channels overexpression in undiseased ventricular myo-
cytes, mimicking their spontaneous pathologic expression in 
HF, indeed leads to abnormal ventricular automaticity via 
If-dependent spontaneous depolarisations in the ventricular 
myocardium [8]. The abnormal, If-dependent electrical activ-
ity in the ventricular myocardium is enhanced by adrenergic 
stimulation [8, 10], and it is sensitive to pharmacological 
inhibition with ivabradine consistent with a direct, causal 
role of If [8]. 
It is important to realise that the pathologic, functional 
If expression in ventricular myocytes [6, 7, 12] leading to 
abnormal automaticity is just one of several mechanisms that 
promote ventricular arrhythmia in HF; others include delayed 
afterdepolarisations and re-entry [11, 20, 21]. However, 
mapping experiments have demonstrated that ventricular ar-
rhythmias in HF are mainly due to nonreentrant mechanisms 
[21], an effect consistent with a role of If-dependent abnormal 
automaticity causing ectopic electrical activity [8, 11].
CLINICAL RELEVANCE OF VENTRICULAR 
ARRHYTHMOGENICITY SUPPRESSION  
WITH IF BLOCKADE: LINES OF PRIOR  
EVIDENCE IN HEART FAILURE PATIENTS
The pivotal SHIfT study of ivabradine in human HF ran-
domised 6558 patients with chronic HF on guideline-based 
optimised HF therapy (ACE inhibitor and/or ARB in 93% 
and beta-blocker at maximally-tolerated dose in 93%) [13] 
to ivabradine vs. placebo. SHIfT was incapable of any direct 
evaluation of the anti-arrhythmic effect of “ventricular” 
If-blockade for two fundamental reasons. First, arrhythmic 
death, unfortunately, was not an endpoint in SHIfT [13] and 
because it was not evaluated, SHIfT reports do not include 
any specific data on arrhythmic death [13]. Secondly, history 
of any VT (unless a cardioverter-defibrillator, ICD, was already 
implanted) or — in those with ICD — ICD shock within six 
months prior to randomisation, formed exclusion criteria in 
SHIfT [13]. Despite these limitations, SHIfT has provided 
several lines of indirect evidence that the If blocking effect of 
ivabradine in the ventricular myocardium might be clinically 




the primary (combined) endpoint of cardiovascular death or 
hospitalisation for worsening HF reduced by ivabradine (24% 
vs. 29%, p < 0.0001 [13], but also ivabradine significantly 
reduced cardiovascular deaths (16% vs. 22%, p = 0.048 [15]) 
and deaths from HF (4% vs. 8%, p = 0.019 [15]). Since ma-
lignant ventricular arrhythmia is one of the principal mecha-
nisms of death in HF [20, 24], the reduction in HF death 
and overall cardiovascular death with ivabradine treatment 
in SHIfT is likely to have occurred in part due to reduction 
in arrhythmic death.
The significant bias in SHIfT towards the lower-risk HF 
patient population (exclusion of patients with VT or ICD 
shock within six months prior to randomisation [13]) a priori 
minimised the potential of SHIfT to detect the benefit of ma-
lignant ventricular arrhythmia suppression occurring through 
“ventricular” If inhibition with ivabradine. Nevertheless, ECG 
Holter recordings in SHIfT (albeit limited to a small fraction of 
the SHIfT population and limited to 24 h on a single occasion 
at baseline and 24 h on a single occasion at eight months) 
clearly suggested a reduction in non-sustained VT with ivabra-
dine (10% on ivabradine vs. 15% on placebo; absolute risk 
reduction by 5% and relative risk reduction by 33%) [15]. It is 
widely appreciated that while 24-h Holter recordings provide 
relatively reliable information on overall heart rate control (the 
focus of ivabradine vs. placebo investigation in SHIfT Holter 
substudy [15, 16]), this (short) recording duration is insufficient 
to determine rare arrhythmic episodes [25] due to a profound 
mismatch between the life-threatening ventricular arrhythmia 
prevalence (risk) vs. recording duration of only 24 h. Regretta-
bly, 24-h ECG Holter recordings were obtained only in 501 out 
of 6558 patients in SHIfT (7.6%), resulting in the Holter 
analysis being underpowered for life-threatening ventricular 
arrhythmias and thus lacking the “statistical significance” of 
the anti-arrhythmic effect of ivabradine in HF [15]. In conse-
quence, the 1/3 reduction in non-sustained VT with ivabra-
dine in the SHIfT Holter substudy, although reported [15], 
has passed largely unnoticed.
IVABRADINE ATTENUATION OF VENTRICULAR 
ARRHYTHMIA IN DECOMPENSATED HEART  
FAILURE WITH BACKGROUND ADRENERGIC  
STIMULATION: NOVEL CLINICAL DATA 
Sympathetic stimulation is a well-known, clinically-relevant 
trigger of ventricular arrhythmias in HF (including life-threaten-
ing ones) [20, 21]. At the same time, catecholamines potently 
stimulate the If current in the ventricular myocardium in hu-
man HF by reducing its activation threshold and increasing 
the amplitude of the current in human failing cardiomyocytes 
[6, 7]. Ventricular ectopic beats in patients with HF are an 
important risk factor for VT and arrhythmic death [26]. 
New clinical research data from the study on ‘Effects of 
ivabradine and beta-blocker therapy on dobutamine-induced 
ventricular arrhythmias in heart failure’ [2] indicate suppres-
sion of ventricular arrhythmogenicity in decompensated HF 
with ivabradine treatment in the presence of background 
adrenergic stimulation of increasing intensity. Using 
a clinically-relevant study protocol, Mert et al. [2] effectively 
overcame the challenging logistics and randomised 58 pa-
tients with decompensated HF and left ventricular ejection 
fraction < 35% requiring pharmacologic inotropic support 
to ivabradine vs. placebo (1:1). Continuous ECG recordings 
were performed at baseline, on ivabradine vs. placebo prior 
to dobutamine administration, and then at increasing doses 
of dobutamine with ivabradine or placebo on board [2]. 
Ventricular arrhythmogenicity was compared with that in 
a non-randomised group of similar patients on beta-blocker, 
subjected to increasing doses of dobutamine according to 
a similar protocol. The present findings [2] suggest a reduction 
in ventricular ectopic beats with ivabradine by ≈40% at the 
low and moderate dobutamine dose. Unsurprisingly, the high 
dobutamine dose was able to overcome the antiarrhythmic 
effect of ivabradine, presumably due to the magnitude of 
concurrent recruitment of ventricular arrhythmia mechanisms 
other than If-dependent enhanced automaticity. Because the 
majority of patients on ivabradine today are also on a be-
ta-blocker [13], a clearly missing ‘natural’ study group in this 
work [2] is that of a combined ivabradine plus beta-blocker. 
Thus, it remains to be elucidated whether the anti-arrhythmic 
effect of ivabradine is additive to the anti-arrhythmic effect 
of beta-blockade. Importantly, the emerging technical ability 
to monitor heart rate continuously in a non-invasive manner 
[27] may overcome the shortcomings of ECG Holter record-
ings limited to 6-h intervals [2] or single-occasion 24 h [14, 
15, 25]. The new technology [27] will conveniently enable 
long-term evaluation of the clinical significance of ventricular 
arrhythmia attenuation with ivabradine in human HF. 
CONCLUSIONS
In conclusion, evidence in human cardiac tissue from failing 
hearts explanted at heart transplantation and in experimental 
models of human disease [6–11, 17, 22] shows consistently 
that If activation in ventricular myocardium may enhance 
ectopic electrical activity and promote arrhythmogenesis in 
HF [17, 22]; an effect particularly significant in the presence 
of background adrenergic stimulation [6, 7, 16]. 
The popular assumption that the action of If inhibitors is 
limited to the sinoatrial node [1] is true for the healthy heart 
[5, 22] because in the healthy heart f-channels are functionally 
expressed only in sinoatrial node cells. In myocardial disease, 
and in HF in particular, the f-channels undergo a pathologic, 
functional expression in the ventricular myocardium [6, 7, 
12, 23]. By favouring spontaneous diastolic depolarisation in 
ventricular myocytes, the If current in human failing cardio-
myocytes may contribute to the increased risk of malignant 
ventricular arrhythmias and death in patients with HF [6–10]. 
Prior work demonstrated that ventricular If is responsive to 
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blockade with ivabradine [8, 10]. With a smart clinical study 
design leading to novel findings, Mert et al. [2] indicate today 
an anti-arrhythmic effect of “ventricular” If blockade with 
ivabradine leading to reduction in ventricular arrhythmias 
in the presence of background adrenergic stimulation in hu-
man HF. This work [2] opens a new clinical research avenue 
and it should encourage further studies of the relevance of 
“ventricular” If blockade in the field of research that remains 
continuously active [9, 22, 23, 28–31] due to the fundamental 
clinical implications for HF patients. 
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